Breast Cancer

ASCO’s updated breast cancer follow-up guideline replaces routine, one-size-fits-all surveillance with a 3-tier, risk-based model.

Paxalisib produced a 100% clinical benefit rate and an 83% objective response rate in patients with metastatic triple-negative breast cancer.

The regulatory submission to expand the gedatolisib label to HR+/HER2-, PIK3CA-mutant advanced breast cancer is based on positive VIKTORIA-1 trial data.

Ami Shah, MD, Megan Kruse, MD, and Ruta Rao, MD, discuss DESTINY-Breast09, -11, and -05 data on trastuzumab deruxtecan in HER2-positive breast cancer.

The phase 2 Neo-CheckRay trial findings showed that adding durvalumab to radiation and chemotherapy nearly tripled pCR rates in PD-L1–negative ER+/HER2− breast cancer.

Gedatolisib plus fulvestrant, with or without palbociclib, now holds NCCN Category 1 status for HR+/HER2– PIK3CA wild-type advanced breast cancer.

Kay Yoon-Flannery, DO, MPH, FACS, discusses da Vinci Single Port robotic mastectomy, ranging from technique and patient selection to outcomes.

Explore modern metastatic breast cancer care: longer survival, smarter symptom control, caregiver support, and steps to close racial treatment gaps.

A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.

In 50,845 SEER patients aged ≥70 years with stage I ER-positive breast cancer after BCS, radiation omission was not associated with inferior BCSS (aHR, 0.95; 95% CI, 0.87-1.04), though radiation conferred modest OS benefit, supporting selective de-escalation in older patients.

In a prospective pilot of 74 patients enriched for under-represented risk factors, 15-fraction breast/chest wall RT with SIB yielded 10-year LRFS of 93.1%, DMFS of 94.2%, and OS of 89.2%, with no grade 3 brachial plexopathy or significant lymphedema, supporting condensed SIB use in routine practice.

In 536,783 NCDB breast RT courses from 2020 to 2023, 5-fraction RT rose from 4.3% to 17.4% overall, with uptake significantly lower among uninsured patients (6.9%), Black patients (9.4% vs 12.2% White), and mid-size metro areas, revealing persistent access disparities.

Dosing has resumed in the INVINCIBLE-4 trial of INT230-6 plus standard therapy in early-stage triple-negative breast cancer.

Sara Hurvitz, MD, FACP, discussed the IV formulation of gedatolisib and its favorable toxicity profile compared with oral PI3K inhibitors in breast cancer.

In an NCDB cohort of 536,783 breast radiation courses from 2020 to 2023, 5-fraction RT utilization rose from 4.3% to 17.4%, with overall 10.7% adoption across the 4-year period.

This narrative review synthesizes evidence and sarcoma-based extrapolation to support multicatheter interstitial HDR brachytherapy as a feasible chest-wall irradiation strategy for selected high-risk malignant phyllodes tumors.

Sara Hurvitz, MD, FACP, explained why the FDA approval of gedatolisib is practice changing for patients with HR+/HER2– metastatic breast cancer.

Geospatial analysis of 77 Miami-Dade zip codes found 49 containing no mammography facilities, with zero-facility areas concentrated in lower-income, majority-Hispanic/Latino and Black neighborhoods.

A Gaussian linear regression model of US county-level data found breast cancer mortality risk highest among African American individuals and those in rural, high-ADI counties.

The FDA has approved the gedatolisib combination for HR+/HER2– PIK3CA wild-type advanced breast cancer post-CDK4/6i, based on the phase 3 VIKTORIA-1 trial.

In a nationally representative cross-sectional analysis of 6774 women aged 40 to 49 years, overall mammography prevalence was 60.3% with no significant change from 2019 to 2023, while Hispanic women showed a 6.5-percentage-point decline and insurance status remained the strongest enabling factor for uptake.

In 77 biopsy-proven cystic breast lesions, radiologists achieved significantly higher diagnostic accuracy than the KOIOS DS™ AI tool for malignant cystic lesions (92% vs 76% BI-RADS/suspicious classification).

Mayo Clinic oncologists weigh first-line ADC options in metastatic TNBC, tackling biomarker timing, sequencing, and real-world toxicity management from fatigue to ocular events.

A 2-phase U-Net trained on abnormality-focused patches achieved a mean Dice coefficient of 0.58 and detected 77.8% of mammographic lesions on a 55-image test set, with 100% detection of large lesions but resolution-dependent failures for small abnormalities.

GBD 2023 data analysis found India’s age-standardized breast cancer incidence at 28.7 per 100,000 women, with national mortality tripling from 33,151 to 101,621 between 1991 and 2023 and DALYs quadrupling, with the steepest increases in Jharkhand and the highest incidence in Delhi.